OUR PATENTS
PIONEERING IN VIVO GENE EDITING OF THE MICROBIOME
Recent IP Portfolio Highlights
Successful outcome in US CRISPR patent interference against SNIPR Biome
“In November 2021, US “Interference” proceedings resulted in cancellation of five US patents owned by SNIPR TECHNOLOGIES. It was concluded that the technology claimed in those patents was invented earlier by The Rockefeller University. The University have their own earlier patent filing focused on that technology, which is licenced exclusively to ELIGO.”
ELIGO v SNIPR: a reflection on IP strategies in a competitive environment. Microbiome times. Feb 7, 2022
2013
earliest priority
in the field
25
patent
families
100+
bacterial
species
100+
therapeutic
indications
A broad and robust patent estate
Eligo controls a diverse and robust patent portfolio of 25+ patent families exclusively licensed to Eligo or owned by Eligo. This portfolio covers all aspects of gene editing of the microbiome with a pioneering IP position supporting Eligo’s three main applications:
Gene removal
Highly specific elimination of disease-promoting gene(s) and specific killing of the bacterial strains carrying the gene(s), via the delivery of a CRISPR system
Gene modification
Precise in vivo modification of a disease-promoting bacterial genetic sequence to remove disease triggers without killing the bacteria, via delivery of a base editor.
Gene addition
Alleviates a disease by delivering therapeutic gene(s) that, once expressed by target bacterial species of the microbiome, modulate a specific aspect of the disease mechanism.
✓ Any CRISPR system
✓ Any target bacteria
✓ Any type of delivery payload
✓ Earliest patent priority in the field
✓ Any genome editing system
✓ Any target bacteria
✓ Any type of delivery payload
✓ Earliest patent priority in the field
✓ Any therapeutic gene
✓ Any target bacteria
✓ Any type of delivery payload
✓ Earliest patent priority in the field
Focus on the breadth and depth of our CRISPR IP
The IP estate controlled by Eligo broadly covers compositions of matter and methods relying on the CRISPR-Cas antimicrobials technology, i.e. sequence-specific gene removal and killing of bacteria with CRISPR-Cas.
While some claims are directed to specific bacterial species, specific delivery vector encoding the CRISPR-Cas system or specific CRISPR-Cas system, other types of claims are directed to :
• method of killing with any bacteria, with any type of delivery vector and/or with any CRISPR-Cas system
• pharmaceutical composition comprising any type of delivery vector and/or any CRISPR-Cas system and/or for killing of any type of bacteria
Therefore, any bacteria targeted by any type of DNA payload encoding any CRISPR-Cas system are covered, together with any combination thereof.
—-
In addition, methods involving the treatment of disease with engineered phages encoding a CRISPR-Cas system also fall under the the CRISPR IP controlled by Eligo, as well as pharmaceutical compositions comprising engineered phages encoding a CRISPR-Cas system for killing of bacteria.
